Press Releases

May. 06 AbbVie to Present at the Bank of America Securities Healthcare Conference PR
May. 05 AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week® PR
May. 04 SKYRIZI® (risankizumab) Secures Listing on Ontario and Alberta Formularies in Ulcerative Colitis AQ
Apr. 30 AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec GL
Apr. 30 Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month PR
Apr. 29 AbbVie : ABBV 1Q26 Press Release Final PU
Apr. 29 AbbVie: Q1 Earnings Snapshot AQ
Apr. 29 AbbVie Reports First-Quarter 2026 Financial Results PR
Apr. 28 AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata PR
Apr. 28 RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF inhibitor AQ
Apr. 27 AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease PR
Apr. 24 AbbVie Provides Update on TrenibotulinumtoxinE Biologics License Application in the U.S. AQ
Apr. 23 AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S. PR
Apr. 22 AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus PR
Apr. 20 AbbVie and BioLabs Team Up to Support Life Sciences Innovation in Canada AQ
Apr. 14 Erin Lichy Gets Real About Her Natrelle® Breast Augmentation PR
Apr. 13 AbbVie Showcases Late-Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE) in Platinum-Sensitive Ovarian Cancer (PSOC) at SGO 2026 AQ
Apr. 12 AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026 PR
Apr. 09 BOTOX(R) Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through 'The Confidence Collective' for Fourth Year AQ
Apr. 08 AbbVie : moves to close loopholes and strengthen accountability in 340B program PU
Apr. 08 BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year PR
Apr. 08 AbbVie Defeats Genetic Privacy Class Action Because Request For Plaintiff's Family Medical History Was Not A "Condition Of Employment" AQ
Apr. 07 Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin PR
Mar. 31 /C O R R E C T I O N -- AbbVie/ PR
Mar. 31 AbbVie to Host First-Quarter 2026 Earnings Conference Call PR
No results for this search